protocol, surely contributed to the higher risk of developing a thrombosis anyway.
[9] Kloviate J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. We analysed the von-Willebrand factor, and all patients developed von-Willebrand syndrome. Nearly all patients, whether they take aspirin or not, will have impaired thrombocytic function.
Dr Edmunds: I am going to comment because all who are working with these devices on a chronic basis know that blood is traumatized as it goes through the machine. You need to measure F1.2 to find out how much thrombin is being generated, and you need to measure D-dimer, or some other measure of fibrinolysis, because that is also going on. Just saying you did not have any strokes depends on how fine you are able to see a stroke or find a stroke. And if I have to have one of these devices, and I am closer to it than anybody else in the room probably, I do not want to lose my head.
Dr Menon: Yes, that is absolutely right. Dr Edmunds: There is not much left anyway. Dr Menon: Every 4 weeks, we have a close examination of every patient during the whole period, and we define stroke as having a neurologic deficit persisting for more than 24 h according to the CT scan findings.
Dr D. Loisance (Paris, France): I still do not understand how you can say that there is no thrombus formation in your patients. You do not show us any evidence about thrombus formation, and we are wondering, as was stated before, about the D-dimers. It is at least the minimum you should show us.
Dr Menon:
In every patient, we tested the free haemoglobin and LDH of course, and it was almost within normal levels. And even the parameters of the LVAD pump seem to be very okay in every patient. We are testing it every 4 weeks. of pump thrombosis, the start of the pilot trial was under the impression that, for the new technology, anticoagulation and antiplatelet therapy should be as strong as possible.
In hindsight, this was not necessary and was causing harm to the patients. Therefore, in subsequent recommendations, anticoagulation therapy became less and less aggressive. Following the current guidelines, the group from Aachen reports favourable results in this journal in terms of bleeding and thrombosis in patients implanted with the HeartMate II.
In the meantime, it was recognized that these rotary blood pumps cause an acquired von Willebrand Syndrome. Shear stress, which seems unavoidable, when energy is transferred to the blood with miniature impellers at high speed, is the cause of the largest monomers of the von Willebrand factor (vWF), being the biggest molecule in the blood, to change their tertiary structure exposing the cleaving sites to a hydrolytic enzyme. Thereby, a substantial decrease of the largest monomers without changing the total amount of vWF is found. This leads to a clinical condition that is well known in patients with severe aortic stenosis: an impairment of primary haemostasis and the Heyde syndrome: Patients suffer from minor bleeding from the mucosa that may lead to nose and mouth bleeds. In addition, major bleeding episodes may occur at arteriovenous malformations in the small bowel [1] . These are not easy to find and to treat.
These findings triggered some programmes, like ours, to withdraw antiplatelet medication and just use coumadin. In most programmes antiplatelet therapy is continued, but the target international normalized ratio was further decreased.
There were reports that in bleeding episodes anticoagulation was withdrawn completely without any adverse events (AEs). So the question arose, is anticoagulation at all necessary in HeartMate II patients?
Currently it seems, pump replacements for pump thrombosis have become more frequent. One reason, of course, is the increased number of implants, but in addition it leads to the conclusion that anticoagulation is necessary in VAD therapy. We have reached the other end of the spectrum -going from 'as much as possible' in 2004 to 'almost nothing at all' 8 years later. In this debate, the paper of Dr Menon et al. [2] is leading the way, and in a direction that most experienced centres would agree with: the pendulum swinging back to a moderate anticoagulation protocol.
But is this the end of this story? VAD therapy proved in the last 8 years that the long-term stability of the pumps is not an issue anymore. Patients can be supported not only as a bridge to transplantation, but as a definitive therapy for end-stage heart failure. The devices have been in numerous trials to show that. Therefore, the use of this technology has increased substantially, because the number of heart transplant procedures no longer matches the demand of patients in heart failure.
Despite the success of VAD therapy, given the number of patients in need, why is the number of implants still at a relatively low level? One factor is reimbursement, the others are AEs in VAD therapy.
These are linked in the way that future reimbursement of chronic support with VADs can only be expected when a gain in quality-adjusted life years is proven.
What are the most limiting AEs in long-term therapy? There is an incidence of bleeding and thrombosis, possibly leading to cerebrovascular accidents (CVAs) or pump thrombosis. Still Menon et al. describe a low incidence of CVAs, although the mean follow-up was limited to only 240 days. Truly, it is much less than years ago, but is it at an acceptable level? I have my doubts: the follow-up in this article as well as in most publications is too short to give definitive answers: what is the incidence of CVAs in a 5-year perspective?
In addition, a driveline infection is still the other major AE: the incidence is high and requires dedicated outpatient care to decrease injury to the driveline. Recently, most investigators in this field have agreed to find correlations of infections with subsequent CVAs. It seems there is a delicate balance between thrombosis and bleeding in VAD patients that can be challenged by many factors.
So what is the bottom line? Moderate anticoagulation protocols are currently state-of-the-art in VAD patients with rotary blood pumps. In addition, this technology allowed for the first time to consider VAD as a real treatment option in heart failure. But can we show a gain in quality-adjusted life years [3] ? We have proven a survival benefit [4] , but the quality of life and the absence of serious AEs in a 5-year perspective remain to be shown.
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